ImmunityBio (IBRX) Extends Gains to 10th Day on 700% Anktiva Sales Jump; Time to Book Profits?

We precocious published 10 Stock With Eye-Popping Gains; 5 Are connected Fresh Highs. ImmunityBio Inc. (NASDAQ:IBRX) was 1 of the apical performers connected Thursday.

ImmunityBio extended its winning streak to a 10^th consecutive time connected Thursday, soaring 30.79 percent to adjacent astatine $3.95 apiece, arsenic investors loaded portfolios aft achieving a 700 percent leap successful preliminary revenues from Anktiva for the full-year 2025.

During the period, ImmunityBio Inc. (NASDAQ:IBRX) said that it registered $113 cardinal successful revenues from Anktiva amid beardown demand. Anktiva is the archetypal FDA-approved immunotherapy for non-muscle invasive bladder cancer.

In the 4th fourth alone, ImmunityBio Inc. (NASDAQ:IBRX) posted $38.3 cardinal successful nett revenues, marking a 431 percent summation from the aforesaid play past year.

“ImmunityBio continues to spot accrued income momentum supporting a inclination of increases quarter-over-quarter with a 54 percent 4th implicit 4th portion measurement maturation complaint during FY 2025,” it said.

In different caller news, ImmunityBio Inc. (NASDAQ:IBRX) has secured the support of the Saudi Food and Drug Administration to merchantability and marketplace Anktiva, successful operation with an immune checkpoint inhibitor, successful Saudi Arabia.

“This support represents a important measurement guardant for lung crab patients successful the Kingdom of Saudi Arabia and a meaningful milestone that we anticipation volition pave the mode toward further approvals crossed a portion wherever lung crab claims acold excessively galore lives each year,” said Executive Chairman Patrick Soon-Shiong.

While we admit the imaginable of IBRX arsenic an investment, our condemnation lies successful the content that immoderate AI stocks clasp greater committedness for delivering higher returns and person constricted downside risk. If you are looking for an highly inexpensive AI banal that is besides a large beneficiary of Trump tariffs and onshoring, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.